Clinical Trial Update: Coxib-inhibition of Duodenal Polyp Growth in FAP [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial evaluating a COX-2 inhibitor (coxib) for reducing duodenal polyps in patients with familial adenomatous polyposis has been term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duodenal Polyposis
• Familial Adenomatous Polyposis

Snippet

Sponsor: Oslo University Hospital | Conditions: Duodenal Polyposis | Phase 2, Phase 3 | Status: TERMINATED